FDA D.I.S.C.O. Burst Edition: FDA approval of Augtyro (repotrectinib) for locally advanced or metastatic ROS1-positive non-small cell lung cancer

Fri Jan 05 2024

Get AI-powered summaries and transcripts for any meeting, phone call, or podcast.

AI SummariesFull TranscriptsSpeaker Identification

Available on iOS, Android, Mac, and Windows

No transcript available.